Context: The pathogenesis of tyrosine kinase inhibitor-induced thyroid hormone (TH) alterations are still a matter of debate.
S
everal tyrosine kinase inhibitors (TKIs) are reported to be associated with changes in thyroid function tests (TFTs), of which sunitinib is the best studied (1).
Sorafenib is used in the treatment of advanced hepatocellular carcinoma (HCC), renal cell carcinoma, and radioactive iodine-resistant differentiated thyroid carcinoma (DTC) (2) (3) (4) . It has antiangiogenic, antiproliferative, and proapoptotic effects via multiple effector mechanisms, such as inhibition of the vascular endothelial growth factor receptor (5) . In 2011, we reported on two patients with sorafenib-induced thyroiditis (6) ; since then, other cases of sorafenib-induced thyroiditis have been described (7) . Hypothyroidism and adverse effects, such as hypertension, are described to be associated with better prognosis among patients undergoing treatment with TKIs (8, 9) .
The incidence of sorafenib-induced hypothyroidism varies from 18% to 50% (10) (11) (12) (13) (14) (15) . In previous studies (10) (11) (12) (13) (14) (15) , the diagnosis of sorafenib-induced hypothyroidism was only based on increased thyroid-stimulating hormone (TSH) levels. Patients with preceding thyroiditis, a different entity contributing to TSH increase, were not excluded. The pathogenesis of the rise in TSH in nonthyroiditis cases has not been elucidated.
A study in athyroid patients treated with sorafenib suggests that there may be an enhanced peripheral degradation of thyroid hormone (TH) by deiodinase type 3 (D3) (16) . D3 expression has been described in other tumors (17) . Inhibition of TH uptake via the cellular TH transporter [monocarboxylate transporter (MCT) 8] has been shown for sunitinib, imatinib, dasatinib, and bosutinib, but this has not been studied for sorafenib (18) . The effects of TKIs on MCT10-mediated TH uptake into cells are, to the best of our knowledge, unknown.
The aim of the current study was to explore the effects of sorafenib on the hypothalamic-pituitary-thyroid (HPT) axis and peripheral TH metabolism by assessing detailed TFTs in patients without known thyroid disease. By studying patients with intact thyroid glands, we were able to study effects on the HPT axis at different levels. In addition, we studied the consequences of sorafenib on cellular triiodothyronine (T3) uptake in vitro.
Patients and Methods

Patient characteristics
We prospectively studied consecutive patients with progressive metastatic HCC and Child-Pugh A status who were treated with sorafenib between January 2007 and February 2016 in the Erasmus MC Cancer Institute, Rotterdam, Netherlands. Patients routinely started sorafenib at a dose of 400 mg, which was increased in 1 month to 800 mg if deemed safe by the treating physician.
Routine TFT [TSH and free thyroxine (FT4)] levels were determined every 6 weeks. In patients with enough material available, more extensive TFT levels were measured at baseline (t0), after 6 weeks (t6), and at the end of sorafenib therapy (Supplemental Fig. 1) . Patients with at least two laboratory evaluations were included in the study. The study was reviewed by the medical ethical committee of the Erasmus Medical Center (MEC-2015-755); requirements to obtain informed consent were waved.
Clinical outcome
Baseline World Health Organization (WHO) performance status was assessed by the treating physician. Progression-free survival (PFS) was computed as the time from treatment initiation to disease progression according to the treating physician or death (19) . Overall survival was computed as the time from treatment initiation to death. Adverse events were scored following Common Terminology Criteria for Adverse Events v4.0 (20) . The incidence of all-grade hand foot skin reaction, hypertension, gastrointestinal complaints, and thrombocytopenia was scored. Severe liver toxicity criteria were grade 3 or 4 liver test disturbances in liver transaminases, g-glutamyl transferase, and alkaline phosphatase or grade 2 bilirubin disturbances.
TFTs
Serum was centrifuged and stored at 220°C immediately after withdrawal. TSH (reference value, 0.4 to 4.3 mU/L) was measured using the Immulite 2000 platform (Siemens, Erlangen, Germany). FT4 (reference value, 11 to 25 pmol/L), thyroxine (T4) (reference value, 58 to 128 nmol/L), and T3 (reference value, 1.4 to 2.5 nmol/L) were measured using the Vitros ECi immunoanalyzer (Ortho-Clinical Diagnostics, Raritan, NJ). Reverse triiodothyronine (rT3) (reference value, 0.21 to 0.54 nmol/L) was measured by in-house radioimmunoassay (21) . Intra-and interassay variability coefficients of all assays were ,11% (22) . T3/rT3 (reference value, 2.65 to 7.65) and rT3/T4 3100 (reference value, 1.4 to 3.1) ratios were calculated as a proxy for peripheral deiodinase activity. Thyroid peroxidase antibodies (TPO-Abs) (reference value, ,100 IU/mL) were measured using the ImmunoCAP method (Phadia 250, Uppsala, Sweden). TSH receptor antibodies (TSHR-Abs) (reference value, ,0.9 IU/L) were measured using the 2009-2012 TRAK LIA test (Brahms, Hennigsdorf, Germany) and the 2012-2015 TRAK Kryptor test (Brahms, Hennigsdorf, Germany), both WHO calibrated.
In vitro experiments
Effects of sorafenib on cellular uptake of T3 by human MCT8 and MCT10 Materials. Dulbecco's phosphate-buffered saline with calcium and magnesium and GlutaMAX medium was obtained from Life Technologies (Bleiswijk, Netherlands); culture dishes were from Corning (Schiphol, Netherlands); COS1 cells were from ATCC; bovine serum albumin, D-glucose, and T3 were from Sigma-Aldrich (Zwijndrecht, Netherlands); transfection reagent X-tremeGENE9 were from Roche (Almere, Netherlands); and Na 125 I was from Perkin-Elmer (Groningen, Netherlands). [
125 I] T3 was prepared in our laboratory as described previously (23) . The human MCT8 plasmid pcDNA3-hMCT8 and the human pcDNA3-hMCT10 were obtained as described elsewhere (23) .
Cellular T3 uptake assays. COS1 cells were cultured in 24-well dishes with 0.5 mL Dulbecco's modified Eagle medium/F12 + GlutaMAX medium containing 9% heat-inactivated fetal bovine serum, 2% penicillin/streptomycin, and 100 nM Na 2 SeO 3 . The cells were transfected with 100 ng empty pcDNA3, pcDNA3-hs MCT8, or pcDNA3-MCT10 as described (24) . T3 uptake was tested 48 hours after transfection. The cells were washed with the assay buffer (Dulbecco's phosphate-buffered saline with calcium and magnesium + CaCl 2 + MgCl 2 + 0.1% bovine serum albumin + 0.1% glucose) and incubated for 5 minutes at 37°C with 1 nM (10 5 cpm) [ 125 I] T3 and 0, 1, 10, or 100 mM sorafenib or 0, 1, 10, or 100 mM sunitinib in 0.5 mL assay buffer. After incubation, cells were washed with the assay buffer, lysed with 0.1 M NaOH, and counted in a gamma counter. Data were obtained from three independent experiments, each performed in duplicate.
D3 activity in HCC samples
To exclude a major contribution of D3 expression in HCC to the altered TFTs, we measured D3 in six random patients from whom presorafenib HCC biopsies were available. Tumor tissue was fresh frozen and stored at 280°C until use. Thawed tissue samples were homogenized on ice in 10 volumes of PED10 buffer [0.05 M phosphate, 1 mM EDTA (pH 7.2), 10 mM DTT] using a Polytron (Kinematica AG, Lucerne, Switzerland). Liver D3 activities were measured in duplicate by incubation of tissue homogenate (250 mg protein) for 120 minutes at 37°C with 1 nM [3 0 -125 I]T3 (200,000 cpm) in 0.1 mL PED10 as described elsewhere (25) .
Statistical analysis
Normal distribution was evaluated using the KolmogorovSmirnov test. Residuals that were not normally distributed underwent natural logarithmic transformation, and if still skewed P values were obtained via bootstrapping. Changes in TFTs were analyzed using a paired sample t test and if not normally distributed via a paired Wilcoxon signed-rank test. False discovery rate correction for multiple comparisons proposed by Benjamini (26) was applied. Logistic regression analysis was used to determine the association between change in TFTs and adverse effects. Median survival time was calculated using Kaplan Meier. A Cox proportional-hazard regression model adjusted for age, sex, WHO performance status, and average dose of sorafenib was used for the survival analysis. Proportional hazard and linearity assumptions were met. Twoway ANOVA with correction for repeated testing and post hoc analysis with a paired t test was used for sorafenib-induced inhibition of MCT8 and MCT10 transport of T3 into cells. Analyses were performed using SPSS version 23 (SPSS Inc., Chicago, IL).
Results
Patient characteristics
Blood samples were collected from 57 patients with HCC. One patient had a TSH $10 mU/L before therapy and was therefore excluded from the analyses. None of the patients had pre-existent hyperthyroidism or hypothyroidism or used drugs interacting with TFTs, such as amiodarone and corticosteroids. This resulted in a final population of 56 patients, 44 (79%) of whom were male. Median age was 67 years [interquartile range (IQR), 57 to 71 years], and median WHO performance status was 1 (IQR, 1 to 2).
Thyroiditis
Four patients (7%) developed thyroid disease, with a pattern consistent with thyroiditis. Two of these patients have been reported in detail (6) , with clearly elevated TPO-Ab (866 IU/mL) or TSHR-Ab (368 IU/L) levels at the time of thyroiditis. The other two patients also showed markedly increased TPO-Ab (1302 and 439 IU/mL) and TSHR-Ab (19 IU/L) levels at the time of thyroiditis. Prospectively, both patients had elevated TPO-Ab levels before initiation of sorafenib treatment (140 and 343 IU/mL). In comparison, none of the 52 patients without thyroiditis had TPO-Abs, and only six patients (12%) showed mildly elevated TSHR-Ab levels (median, 1.7 IU/L; IQR, 1.1 to 1.9). Ultrasound was not routinely performed prospectively.
Patients with thyroiditis had a median PFS of 16.3 months [95% confidence interval (CI), 6.1 to 26.5], and patients without thyroiditis had a median PFS of thyroiditis 4.9 months (95% CI, 2.3 to 7.5). Median overall survival was 18.5 months (95% CI, 0.1 to 43.5) vs 10.8 months (95% CI, 8.6 to 13.0), respectively. We refrained from statistical analysis due to small patient number.
TFTs
Patients with thyroiditis were excluded from subsequent analyses of TFTs. Five out of the remaining 52 patients had mild subclinical baseline thyroid dysfunction: three patients had an isolated TSH elevation (5.14, 5.15, and 6.59 mU/L), and two patients had a low TSH (0.25 and 0.39 mU/L).
In 14 of the other 47 patients (30%), TSH or FT4 became elevated above the upper limit of normal during treatment. Overall, TSH and FT4 levels rose significantly after start of treatment (Fig. 1) . Similarly, rT3 and T4 levels increased significantly (Table 1) , whereas the serum T3/rT3 and T3/T4 ratios significantly decreased (Fig. 1) . These changes in TFTs occurred within 6 weeks after start of treatment and persisted until the end of treatment.
In vitro experiments
Cellular T3 uptake mediated by MCT8 was significantly and dose-dependently inhibited by sorafenib, and very similar effects were observed with sunitinib (Fig. 2) . Both sorafenib and sunitinib had marginal effects on T3 uptake by control cells transfected with empty vector and on T3 uptake were induced by transfection of cells with MCT10. The short exposure of the cells to sorafenib and sunitinib (5 minutes) and the differential effects of the inhibitors on MCT8-mediated vs MCT10-mediated and background T3 uptake argue against an important contribution of possible cytotoxic effects of sorafenib and sunitinib in these experiments.
The average D3 activity in the HCC tissue before sorafenib treatment was 1.17 (IQR, ,0.1 to 1.63) fmol/min/mg protein. This was not increased compared with the D3 activities in historical control livers (liver biopsies of patients who died of severe brain damage, taken within minutes after death) that we studied previously (27) .
Clinical outcome
An increase in TSH level was associated with a deterioration of PFS (Supplemental Table 1 ). This negative effect of TSH on PFS persisted in a multiple Cox-regression analysis with correction for age, sex, WHO performance status, and average dose of sorafenib (Fig. 3) . Adding response evaluation criteria in solid tumors (28) to the model did not influence the results. There was no association of FT4 with PFS. TSH showed the same trend for overall survival but did not reach statistical significance (Supplemental Table 1 ). Changes in TFTs were not correlated with adverse events (Supplemental Table 1 ).
Discussion
In this cohort of sorafenib-treated patients with HCC, we demonstrate that sorafenib affects TFTs via multiple mechanisms. Thyroiditis occurred in a small percentage of patients, whereas there was a combined increase in TSH and FT4 in the remaining patients, which suggests a central effect on the HPT axis. Finally, there was a decrease in the T3/rT3 and T3/T4 ratios, suggesting additional effects on the peripheral metabolism of TH.
Thyroiditis
The incidence of thyroiditis was 7%, compared with 23% (14) and 5% (11) in other sorafenib cohorts and 40% (29) in Figure 1 . Change in TFTs at t0, t6, and end of therapy (tv). Changes in TFTs were analyzed using a paired sample t test and if not normally distributed via a paired Wilcoxon signed-rank test. False discovery rate correction for multiple comparisons proposed by Benjamini (26) was applied. **, P , 0.01; ***, P , 0.001. patients treated with sunitinib. The incidence of subacute thyroiditis in the general population is much lower at around 12.1 cases per 100.000/y (30) . However, we cannot draw conclusions on the basis of our observations because only four patients developed thyroiditis in this cohort.
Altered sensitivity of the HPT axis
Thirty percent of patients developed TSH or FT4 levels above the normal range during treatment. Median TSH and FT4 levels rose significantly. This simultaneous increase of TSH and FT4 suggests an altered set-point of the HPT axis because an increase in FT4 would normally be accompanied by a decrease in TSH. For other TKIs, such as axitinib, an isolated increase in TSH accompanied by TH levels within the normal range has also been described (31) . This altered set-point could be explained at several levels because not only serum levels of FT3 and FT4 but also TH transport into the cell and intracellular ]T3 in the absence or presence of 1, 10, or 100 mM sorafenib or sunitinib as described in Materials and Methods. T3 uptake by cells transfected with MCT8 or MCT10 is corrected for T3 uptake by control cells transfected with empty vector (EV). T3 uptake is expressed as mean (standard error of mean) percentage of that in the absence of sorafenib or sunitinib of three independent experiments each performed in duplicate. Two-way ANOVA with correction for repeated testing showed significant change in T3 uptake after for sorafenib (P , 0.02) and sunitinib (P , 0.05). Post hoc, the significance of the difference between the effects of sorafenib or sunitinib on T3 uptake by MCT8 or MCT10 expressing cells vs control cells is shown in the figure. This was tested by paired t test. *P , 0.05; **P , 0.01.
deiodinase activity are determinants of TH action and the HPT axis set-point (32) .
Our in vitro experiments showed inhibition of MCT8-mediated T3 uptake by sorafenib. MCT8 is one of the transporters that is highly expressed in brain and pituitary (33) , suggesting that sorafenib-induced interference with TH uptake by the hypothalamus or pituitary may be one of the mechanisms.
Alternatively, a sorafenib-induced decrease in deiodinase type 2 activity in the hypothalamus or pituitary (described later) would have similar consequences on the HPT axis setpoint. Alternative explanations could be interference with binding of T3 to its nuclear receptor, a diminished pituitary blood flow due to the antiangiogenic effects of sorafenib (34) , or a reduced clearance of TSH (35) . Future studies should investigate which mechanisms contribute to this altered sensitivity of the HPT axis.
Peripheral TH metabolism
There was a marked decrease in the serum T3/rT3 and T3/T4 ratios, suggesting additional changes in the peripheral metabolism of TH because an isolated change in the HPT axis set-point would not necessarily affect these ratios.
In previous experiments, we showed sunitinib-induced D3 activity in normal rat liver (34) . The decreased T3/rT3 ratio observed in the current study fits with an induction of TH inactivation by D3, as has been described by Abdulrahman et al. (16) . In the case of constant T4 production, increased D3 activity would not only lead to increased rT3 production but also to a decrease in T4 levels. However, in contrast to the study of Abdulrahman et al. (16) , which analyzed thyroidectomized patients on TSH-suppressive doses of levothyroxine, our study was performed in patients with intact thyroid glands. We did not only see effects on peripheral metabolism of TH but also a central effect on the pituitary, with an increase in TSH that would increase T4 production. This likely explains why T4 increases despite the decreased T3/rT3 ratio, which we assume to be caused by an increase in D3 activity. Similarly, the decreased T3/T4 ratio fits with a lower T4 to T3 conversion. The higher T4 production may explain why T3 levels remain stable despite this lower T4 to T3 conversion.
The increase in FT4 and the subsequent decrease in T3/ T4 might suggest that other peripheral TH-metabolizing enzymes are also affected, such as a decrease in deiodinase type 1 or deiodinase type 2. In addition, uptake of TH into cells is rate limiting for subsequent metabolism. Because MCT8 is not only expressed in the brain but also in multiple other tissues (36) and MCT10 is highly expressed in skeletal muscle, kidney, pancreas, and intestine (33) , sorafenib-induced inhibition of T3 uptake by MCT8 and MCT10 may also have contributed to the alterations in peripheral metabolism of TH. Further experiments are needed to investigate the contribution of these different mechanisms in more detail.
Nonthyroidal illness (NTI) is not likely to be a major contributor because (1) changes in T3/rT3 and T3/T4 were most evident in the first weeks after start of treatment and not at the end of study (when the cancer was progressive) and (2) TSH and FT4 may remain normal in mild NTI, but the persistent and progressive increase in TSH and FT4 does not fit the pattern of NTI (37) .
The changes in TH metabolism are independent of changes in binding proteins. A decrease in TH binding proteins would have led to a similar decrease in all iodothyronines, whereas we did see marked changes in the total T3/rT3 and rT3/T4 ratios, in which the binding proteins are both in the numerator and the denominator (38) . Furthermore, measurements of FT4 levels and total T4 levels changed in the same direction.
Clinical outcome
In this study, we found that an increase in TSH is an independent negative prognostic marker for PFS. There was no association between FT4 and survival. In vivo, local hypothyroidism is known to be associated with HCC progression (39) . In patients with other solid tumors, especially basal cell carcinoma, induction of D3 is associated with a hyperproliferative state and carcinogenesis (40) . However, our results seem to be in contrast with two other studies in patients treated with sorafenib or sunitinib, where an increased TSH was negatively associated with tumor progression (10, 13) . It is not yet clear how to explain this inconsistency between these studies. However, there are a few differences between the studies: (1) in the previous studies, only patients with TSH levels above the normal range were investigated, https://academic.oup.com/jcemwhereas we assessed the absolute change of TSH on PFS and survival in all patients (including patients within the reference range); (2) in the previous studies, patients received levothyroxine, which may have affected tumor progression and makes it difficult to compare the results; and (3) in the other studies, patients with thyroiditis, who might have different prognostic profiles, were not excluded. Future studies are therefore needed to unravel if and how the effects of sorafenib on thyroid function can be regarded as a prognostic factor.
Conclusions
Our clinical data demonstrate that sorafenib-induced changes in TFTs are mediated at several levels, with in vitro experiments showing sorafenib-induced inhibition of T3 transport into the cell by MCT8 and MCT10.
